Is treatment with aspirin combined with dipyridamole really more cost-effective than aspirin alone?
Heidebrink
J L
JL
D001241:Aspirin / Q000191:economics / Q000627:therapeutic use*; D002561:Cerebrovascular Disorders / Q000188:drug therapy* / Q000191:economics; D002986:Clinical Trials as Topic / Q000191:economics; D003362:Cost-Benefit Analysis; D004176:Dipyridamole / Q000191:economics / Q000627:therapeutic use*; D004359:Drug Therapy, Combination; D005252:Fees, Pharmaceutical; D006801:Humans; D015201:Meta-Analysis as Topic; D009203:Myocardial Infarction / Q000191:economics / Q000517:prevention & control*; D010975:Platelet Aggregation Inhibitors / Q000191:economics / Q000627:therapeutic use*
D010975:Platelet Aggregation Inhibitors; D004176:Dipyridamole; D001241:Aspirin